51264-68-7

Usage

InChI:InChI=1/C11H12O4/c1-2-14-11(13)8-15-10-5-3-4-9(6-10)7-12/h3-7H,2,8H2,1H3

Upstream product

• 64-17-5 ethanol 
• 37748-09-7 2-(3-formylphenoxy)acetic acid 
• 105-39-5 chloroacetic acid ethyl ester 
• 100-83-4 meta-hydroxybenzaldehyde 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 24602-89-9 [3-(2-nitro-vinyl)-phenoxy]-acetic acid ethyl ester 
• 93306-78-6 3-hydroxymethyl-1-ethoxycarbonylmethoxybenzene 
• 708263-39-2 Z-5-[3-(ethoxycarbonylmethoxy)benzylidene]-2-thiohydantoin 
• 204067-67-4 1-[3-(tert-butyl-dimethyl-silanyloxymethyl)-phenoxy]-2-methyl-propan-2-ol 
• 204067-75-4 {3-[2-ethyl-2-(thiophen-3-ylmethoxy)-butoxy]-phenyl}-methanol 
• 204067-66-3 [3-(tert-butyl-dimethyl-silanyloxymethyl)-phenoxy]-acetic acid ethyl ester 
• 204067-79-8 methanesulfonic acid 3-[2-methyl-2-(thiophen-3-ylmethoxy)-propoxy]-benzyl ester 
• 204067-68-5 3-[3-(tert-butyl-dimethyl-silanyloxymethyl)-phenoxymethyl]-pentan-3-ol 
• 204067-78-7 methanesulfonic acid 3-[2-ethyl-2-(thiophen-3-ylmethoxy)-butoxy]-benzyl ester 
• 204067-76-5 {3-[2-allyl-2-(thiophen-3-ylmethoxy)-pent-4-enyloxy]-phenyl}-methanol 
• 204067-70-9 tert-butyl-dimethyl-{3-[2-methyl-2-(thiophen-3-ylmethoxy)-propoxy]-benzyloxy}-silane 
• 204067-69-6 4-[3-(tert-butyl-dimethyl-silanyloxymethyl)-phenoxymethyl]-hepta-1,6-dien-4-ol 
• 204067-71-0 tert-butyl-{3-[2-ethyl-2-(thiophen-3-ylmethoxy)-butoxy]-benzyloxy}-dimethyl-silane 
• 204067-72-1 {3-[2-allyl-2-(thiophen-3-ylmethoxy)-pent-4-enyloxy]-benzyloxy}-tert-butyl-dimethyl-silane 

Relevant academic research and scientific papers

Comparison between porphin, chlorin and bacteriochlorin derivatives for photodynamic therapy: Synthesis, photophysical properties, and biological activity

The development of novel photosensitizers is a challenging task for photodynamic therapy (PDT). Twelve novel photosensitizers (PSs), including porphins (P1-4), chlorins (C1-4) and bacteriochlorins (B1-4) were synthesized. The bacteriochlorins exhibited the longest absorption wavelength (λmax = 736 nm), which is higher than that of porphins (λmax = 630 nm) and chlorins (λmax = 644 nm). In vitro photodynamic activities on Eca-109 human esophageal carcinoma cells were evaluated by standard assays and all PSs showed photodynamic activity. Among them, B2 displayed the highest phototoxicity and the lowest dark toxicity. In addition, B2 exhibited best photodynamic antitumor efficacy on BALB/c nude mice bearing Eca-109 cells tumor. Therefore, B2 is a powerful and promising antitumor photosensitizer for PDT.

Novel non-peptidic small molecule inhibitors of secreted aspartic protease 2 (SAP2) for the treatment of resistant fungal infections

Targeting secreted aspartic protease 2 (SAP2), a kind of virulence factor, represents a new strategy for antifungal drug discovery. In this report, the first-generation of small molecule SAP2 inhibitors was rationally designed and optimized using a structure-based approach. In particular, inhibitor 23h was highly potent and selective and showed good antifungal potency for the treatment of resistant Candida albicans infections.

INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE

The present disclosure discloses compounds capable of modulating the activity of α- amino-β-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.

2-ALKYLOXY BENZENE FORMYL ARYLAMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention relates to 2-alkoxy benzene formyl arylamine compounds as scheme I , in which the R, G, X, Y, Z are consistent with the detailed description in the patent claim. The compounds can act as sphingomyelin synthase (SMS) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin(SM). This invention also includes compounds as scheme I , their pharmaceutically acceptable salts, pharmaceutical compositions as the active ingredients, and their application in drugs which can prevent and cure diseases caused by SM level abnormal increase. These diseases include atherosclerosis, fatty liver, obesity, type II diabetes, and other metabolic syndromes.

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).

OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Biotransformation of new racemic (R,S)-5-benzylhydantoin derivatives by D-hydantoinases from adzuki bean

In the present work the scope of D-hydantoinase enzyme application was increased towards new racemic (R,S)-5-benzylhydantoin derivatives. Five new substrates for the D-hydantoinase (R,S)-5-(3′-carboxybenzyl)hydantoin, (R,S)-5-(4′-carboxybenzyl)hydantoin, (R,S)-5-(2′-carbomethoxybenzyl) hydantoin, (R,S)-5-(3′-carbomethoxybenzyl)hydantoin and (R,S)-5-(4′(4-ethoxycarboxy)propoxybenzyl)hydantoin were synthesised and converted using a two-step hydantoinase process into their corresponding D-phenylalanine derivatives. In this study two D-hydantoinases from Vigna angularis (adzuki bean) obtained from commercial sources were used: pure, isolated directly from Vigna angularis (V.a.D-HYD) 494 U/g and immobilised, recombinant, cloned and expressed in Escherichia coli (rD-HYD) 53.1 U/g. The results obtained showed that the examined enzymes catalysed hydrolysis of all new substrates into their corresponding N-carbamoyl-D-phenylalanine derivatives. High enantiomeric purities of the resulting D-phenylalanine derivatives were also determined. However, very low conversion yields of (R,S)-5-(3′- carboxybenzyl)hydantoin and (R,S)-5-(2′-carbomethoxybenzyl)hydantoin to corresponding N-carbamoyl-D amino acid were observed. Three D-phenylalanine derivatives: 4-carboxy-D-phenylalanine, 3-carbomethoxy-D-phenylalanine and 4-carbopropoxy-D-phenylalanine were obtained and isolated from the reaction mixtures using ion-exchange chromatography.

AROMATIC RING COMPOUND

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

IMIDAZO [4, 5 - B] PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

Novel Compounds

The present invention provides compounds of formula (I): wherein Ra, Rb, Rc, R1, R2, R3, X1, Y1, Z1, A, n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.